TL011 in Severe, Active Rheumatoid Arthritis Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for TL011 in Severe, Active Rheumatoid Arthritis Patients (NCT01123070), a randomized phase 1 study. The primary outcome is Area Under the Plasma Concentration Versus Time Curve [AUC(0-t)] in Part B.

2. Clinical Question

In broad terms, the study asks how the pharmacokinetic profile after a single course of TL011 infusions compares with that after MabThera infusions, while also collecting safety and pharmacodynamic information. The registry lists rheumatoid arthritis as the condition and describes the purpose as determining TL011 safety and pharmacology in people with severe rheumatoid arthritis. The comparison is specific to the doses, participants, outcome definitions, and observation period recorded for this study; it does not by itself answer broader questions about treatment effects beyond those measures.

3. Trial Design

NCT01123070 is a completed Phase Ib study titled TL011 in Severe, Active Rheumatoid Arthritis Patients. Its official title describes an evaluation of safety, pharmacokinetic, and pharmacodynamic profiles after a single course of TL011 infusions. The registry records randomized allocation, triple masking, and a parallel-group model. Enrollment was 54 participants. The recorded study start was 2010-02-05, and primary completion was 2012-04-23.

The main double-blind comparison was between TL011 1000 mg and MabThera 1000 mg. The registry also identifies a Cohort 1 TL011 500 mg group and a Cohort 2 TL011 1000 mg group in the adverse-event information. The posted primary pharmacokinetic results are for the double-blind groups, with 21 participants in the TL011 group and 18 in the MabThera group for that analysis. Those analysis counts should not be confused with overall enrollment or with the different denominators recorded for safety and other outcomes.

The trial collected pharmacokinetic measures, adverse-event outcomes, a CD19+ B-cell measure, and an American College of Rheumatology response measure. The primary endpoint was AUC(0-t) in Part B from Day 1 to Day 57. Secondary outcomes include measures in Part A and Part B, with timeframes depending on the specific outcome. The registry lists 9 outcome measures overall and 8 posted secondary outcomes.

The registry does not report the allocation sequence method, masking procedures, the detailed protocol for the different cohorts, or the rationale for the planned enrollment. It also does not report a sample-size justification. Those omissions limit what can be inferred about the design decisions beyond the recorded randomized, triple-masked, parallel structure.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Part A was an open label dose escalation for TL011 with two cohorts. Part B was randomized, double blind with two treatment groups to compare TL011 to MabThera. There was an 8 weeks core study period followed by 16 weeks extended follow up period.

Part A Cohort 1 Open Label Period

Part A Cohort 2 Open Label Period

Part B Double Blind Period

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Pharmacokinetics (PK) population included all participants that received at least one dose of 1000 mg TL011 or MabThera and had sufficient plasma concentration results to allow estimation of PK parameters

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent to treat (ITT) analysis set included participants that received at least one dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Area Under the Plasma Concentration Versus Time Curve [AUC(0-t)] in Part B, measured over Day 1 to Day 57.

The primary endpoint is the area under the plasma concentration-versus-time curve, AUC(0-t), in Part B. It is measured from Day 1 to Day 57 and expressed in Day*micrograms per milliliter. AUC is a pharmacokinetic summary of drug exposure across the specified concentration-measurement interval: it reflects both the concentration level and how that concentration changes over time. It is not a direct measure of symptoms or clinical benefit.

The registry summarizes this endpoint using a geometric mean for each treatment group and identifies standard deviation as the dispersion measure. The posted group values are 7571.0 for TL011 and 8377.0 for MabThera, with standard deviations of 2219.0 and 2879.0, respectively. The primary comparison is a geometric mean ratio estimated using ANCOVA. Its reported estimate is 0.930, with a 90% confidence interval from 0.797 to 1.084.

Pharmacokinetic exposure is used to characterize how a drug behaves in the body and to compare exposure profiles between treatments. For this trial, it is a central endpoint because the stated purpose includes evaluating TL011 pharmacology. The confidence interval communicates uncertainty around the relative exposure estimate; it is not a range containing the values for individual participants. The registry does not report the details of the concentration-sampling schedule beyond the endpoint timeframe, nor does it state an equivalence margin for interpreting the ratio.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary analysis is reported as ANCOVA, with the parameter described as a geometric mean ratio. ANCOVA is a regression-based method that compares groups while accounting for covariates included in the model. The registry record does not identify the covariates, transformations, or model details used in this analysis, so the adjustment cannot be reconstructed from the posted summary. The sponsor's reported estimate and interval are therefore the relevant primary inferential results.

What does the ratio represent?

A ratio compares one group summary with another. A value of 1 represents equal geometric means on the ratio scale. A value below 1 means the numerator group estimate is lower than the denominator group estimate, while a value above 1 means it is higher. The reported ratio is 0.930, and its 90% confidence interval runs from 0.797 to 1.084. Because the interval includes 1, the data are compatible with estimates on either side of equal geometric means. This does not establish exact equality.

Geometric means are commonly used for pharmacokinetic measurements because concentration and exposure measures can be skewed. In general, a geometric mean is calculated on a logarithmic scale and then returned to the original scale; it summarizes multiplicative rather than additive variation. The registry reports geometric means and standard deviations for the primary outcome, but does not explain the precise transformation or how the standard deviations were calculated. The ratio analysis is distinct from a simple comparison of the two displayed group means.

How should the confidence interval be read?

In general, a confidence interval describes the uncertainty around an estimate under a specified statistical procedure and its assumptions. A narrower interval indicates greater precision than a wider interval, all else being equal. For a ratio, the reference value for no difference is 1. The interval from 0.797 to 1.084 includes that reference, but also spans values in both directions. The interval should not be read as a range containing most individual participants' exposure values; it concerns the estimated group ratio.

The confidence level for the primary interval is 90%, as recorded in the sponsor analysis. The registry also reports p = 0.426. The p-value describes how unusual a result at least as incompatible with a null hypothesis would be if that null hypothesis and the model assumptions held. It does not measure the probability that the null hypothesis is true, and it does not establish equivalence. Because the registry classifies the analysis as equivalence but does not report the equivalence margin, the inferential meaning of the classification cannot be fully evaluated from the record.

What do the recalculated secondary comparisons add?

The posted secondary comparisons use simple unadjusted calculations from the available group summaries. For the continuous CD19+ B-cell outcome, the calculated mean difference is -1.7, with a confidence interval from -17.28 to 13.88 and an unadjusted p-value of 0.831. For the ACR20 response outcome, the calculated risk difference is 0.092, with a confidence interval from -0.183 to 0.367 and an unadjusted p-value of 0.514. These are not ANCOVA results or sponsor-reported inferential analyses: the registry lists no reported sponsor analyses for these secondary comparisons.

In general, an unadjusted comparison does not account for covariates or the fact that multiple outcomes may be examined. Simple summary-based calculations can be useful for describing the posted data, but can differ from analyses using participant-level data, prespecified models, or adjustments. The recalculated estimates do not replace the sponsor's primary analysis. No discrepancy is flagged in the registry record, but the primary endpoint is reported through the sponsor's analysis rather than a recalculated comparison.

Why can over-dispersion matter?

In general, over-dispersion occurs when a model's observed variation is greater than the variation expected under its assumptions. It can make standard errors too small if the model does not account for the extra variability, leading to confidence intervals that are too narrow and p-values that are too small. The registry does not report an over-dispersion assessment for these outcomes. The primary outcome is analyzed as a continuous pharmacokinetic measure, so over-dispersion is not the central issue for interpreting that reported ANCOVA result. The general concept can matter for count or binary outcomes when a model assumes a particular variance structure, but no such sponsor model is reported for the secondary outcomes.

What do the planning illustrations mean?

The sample-size illustrations are based on the observed effects and specify a two-sided significance level of 0.05, equal allocation, and a normal approximation. The listed rows consider planning for 100% of the observed effect, 75% of the observed effect, and 50% of the observed effect. For the continuous and binary secondary comparisons, the displayed sample sizes are participants per arm for the stated power targets. These calculations are planning illustrations, not observed power and not evidence about the probability that the trial detected an effect. They are not the trial's own design calculation; the registry does not report the trial's sample-size justification.

10. Analyses Reported by the Sponsor

The primary endpoint result is the sponsor's reported ANCOVA analysis of the geometric mean ratio. The estimate is 0.930, with a 90% confidence interval from 0.797 to 1.084 and p = 0.426. The registry labels the analysis as equivalence. The equivalence margin and the criteria used to reach that classification are not reported in the registry record, so the equivalence conclusion cannot be independently assessed from the summary alone.

The recalculated comparisons available for the secondary outcomes are simple, unadjusted calculations based on posted summary statistics. They are not a reanalysis of the primary endpoint, and they do not reproduce the sponsor's ANCOVA. The registry does not list sponsor-reported analyses for those secondary comparisons. Differences in methods and the availability of only summary-level information mean that those recalculations should be treated as descriptive checks, not as replacements for a prespecified analysis.

No discrepancy is flagged between the posted primary result and a recalculated primary result; no recalculated primary comparison is reported. The sponsor's analysis is therefore the primary inferential result to interpret. If a discrepancy between sponsor and recalculated results were present, the sponsor's own analysis would take precedence, but the registry record does not identify such a discrepancy for this trial.

11. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple outcomes, including one primary pharmacokinetic endpoint and several secondary measures. Repeated testing across outcomes can increase the chance of false-positive findings when each result is interpreted without adjustment. In general, a prespecified multiplicity plan may define which endpoint is primary, how secondary tests are ordered, or how significance thresholds are adjusted. The registry record does not report whether a multiplicity strategy was specified, whether the secondary outcomes were considered confirmatory or exploratory, or how any family of hypotheses was defined.

The sponsor's primary analysis is reported with a 90% confidence interval and a p-value. The registry does not state the rationale for the confidence level or provide the statistical analysis plan. It also does not report a prespecified equivalence margin, despite classifying the primary analysis as an equivalence analysis. Consequently, the primary estimate can be described, but the equivalence decision rule cannot be reconstructed.

The record does define the primary pharmacokinetic population: participants who received at least one dose of 1000 mg TL011 or MabThera and had sufficient plasma concentration results to estimate pharmacokinetic parameters. The record does not describe how missing concentration measurements were handled, how many participants lacked sufficient results, or whether any sensitivity analyses were conducted. Missing-data methods for the secondary outcomes are also not reported.

Analysis populations vary across the posted results. The primary pharmacokinetic comparison includes 21 TL011 participants and 18 MabThera participants. The CD19+ comparison and ACR20 comparison use different denominators. Such differences may reflect outcome-specific availability or definitions, but the registry does not give enough detail to determine the reasons. The record also does not report protocol deviations, exclusions after randomization, or whether any analysis followed an intention-to-treat principle.

In general, missing-data assumptions can affect both the estimated treatment contrast and its uncertainty, especially if the reasons for missing observations differ between groups or relate to the outcome. Without a description of missingness and its handling, the robustness of the posted estimates cannot be assessed. The registry also does not report interim analyses, stopping rules, or the full statistical plan. These details should be regarded as unreported rather than inferred from the study design or the results.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: sideroblastic anaemia (4.3%), herpes zoster (4.3%), vertigo (4.0%).

The safety results are descriptive participant counts by recorded group. For serious adverse events, the registry reports 0 of 3 participants at risk in the TL011 500 mg cohort, 0 of 3 in the TL011 1000 mg cohort, 1 of 25 in the double-blind TL011 1000 mg group, and 1 of 23 in the double-blind MabThera 1000 mg group. The registry records 0 deaths in each of these groups.

For other adverse events, the corresponding counts are 0 of 3, 2 of 3, 11 of 25, and 5 of 23, respectively. These figures do not describe severity, duration, recurrence, timing, or whether events were judged related to treatment. They should not be converted into a claim of comparative safety without a defined analysis and the relevant context.

The record also lists Sideroblastic Anaemia at 4.3%, Herpes Zoster at 4.3%, and Vertigo at 4.0% among top serious terms. The registry does not provide additional detail in this listing about the event-level distribution or the basis for those percentages. The smaller cohort denominators and the different groups should be kept in view when reading these summaries. Adverse-event counts alone do not establish that one treatment is safer or less safe than the other.

13. What the Result Does, and Does Not, Mean

The primary result describes estimated pharmacokinetic exposure in the analyzed participants over Day 1 to Day 57. It gives a group-level ratio and an interval expressing uncertainty under the sponsor's ANCOVA analysis. The interval includes the ratio value of 1, so it does not establish a clear difference in geometric mean exposure. At the same time, the interval is not proof of identical exposure, and the record does not state the equivalence margin needed to judge the sponsor's equivalence classification.

The finding concerns a pharmacokinetic endpoint, not a direct clinical outcome. It does not establish that either treatment improves rheumatoid arthritis symptoms, prevents disease progression, or is preferable for an individual. The secondary outcomes provide additional pharmacodynamic, response, and safety descriptions, but the registry does not report sponsor analyses for the posted secondary comparisons and does not report a multiplicity plan. Those results therefore warrant cautious, exploratory interpretation.

The analysis population is defined by dose receipt and adequate concentration results, rather than simply by overall enrollment. Other outcomes have different denominators. The registry does not explain all exclusions or missing measurements, so the results cannot be assumed to represent every enrolled participant in the same way. The sample-size illustrations are planning calculations based on observed effects, not observed power and not a record of how the study was originally sized.

More generally, a result that is not statistically distinct from a reference value does not prove that there is no difference. The estimate, interval, design, analysis assumptions, and prespecified decision criteria all matter. Here, the sponsor reports an equivalence-type analysis, but the registry does not include the margin or full analysis plan needed to evaluate that decision in detail. The most defensible reading is limited to the reported exposure estimate, its uncertainty, and the stated gaps in the registry record.

14. Why This Trial Matters Statistically

This study is statistically informative because it illustrates the distinction between a pharmacokinetic comparison and a clinical-response comparison. The primary endpoint summarizes exposure over time, while the secondary outcomes address pharmacodynamic change, clinical response, and adverse events. Different endpoints require different interpretations and do not automatically support the same conclusion.

It also illustrates why the label attached to an analysis matters. A reported p-value for a difference test does not establish equivalence. Equivalence requires a decision framework that includes a prespecified acceptable range; that margin is not reported in the registry record. Without it, the numerical estimate and interval remain interpretable, but the equivalence claim cannot be fully checked.

The study also highlights the importance of reading denominators alongside results. The primary pharmacokinetic analysis population differs from the denominators for the secondary outcomes and safety summaries. Those differences affect the precision and scope of each finding. They also underline why overall enrollment is not a substitute for the number analyzed for a particular endpoint.

Finally, the secondary calculations and planning illustrations demonstrate the limits of summary-data inference. Unadjusted recalculations can help describe posted results, but they do not reproduce a sponsor model or replace participant-level analysis. Planning illustrations based on observed effects are not observed power and cannot establish how likely the original study was to detect an effect. The registry's missing details about the sample-size rationale, multiplicity, missing data, and statistical plan are therefore important to the interpretation, not merely administrative omissions.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record leaves important design and analysis details unreported. It does not give the sample-size justification, the allocation sequence method, the practical masking procedures, or the full protocol and statistical analysis plan. The study is described as randomized, triple-masked, and parallel, but those labels alone do not establish how these procedures were implemented.

The primary analysis is identified as ANCOVA, but the covariates and model specification are not reported. The record labels the primary comparison as equivalence while omitting the equivalence margin and its rationale. It also does not describe the transformation used for the pharmacokinetic summaries or how standard deviations were calculated. These omissions limit independent assessment of the model and of the equivalence interpretation.

There are differences in analysis denominators across outcomes. The registry defines the primary pharmacokinetic population but does not report detailed participant flow, the number excluded from each analysis, or reasons for missing concentration measurements. Missing-data handling, sensitivity analyses, and protocol deviations are not reported. The record does not establish whether analyses were based on intention-to-treat, per-protocol, or other populations beyond the stated pharmacokinetic definition.

The secondary comparisons are unadjusted recalculations from summary statistics, and sponsor-reported analyses are not listed for them. The registry does not report a multiplicity plan, so the inferential status of those comparisons is uncertain. Safety summaries are counts without event-level timing, duration, attribution, or exposure-time details. These limitations do not invalidate the posted numbers, but they restrict how broadly or causally they can be interpreted.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: TL011 in Severe, Active Rheumatoid Arthritis Patients — NCT01123070.
• Registry record last updated 2021-10-04; status last verified 2021-09.
• Results first posted 2021-10-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01123070 is a completed, randomized, triple-masked, parallel Phase Ib study in severe, active rheumatoid arthritis. Enrollment was 54. The registry records a study start of 2010-02-05 and primary completion of 2012-04-23.

The primary outcome was Part B AUC(0-t) from Day 1 to Day 57. The sponsor reports an ANCOVA geometric mean ratio of 0.930, with a 90% confidence interval from 0.797 to 1.084 and p = 0.426, and classifies the analysis as equivalence. The equivalence margin is not reported in the registry record.

Posted secondary outcomes include CD19+ B-cell change and ACR20 response, with unadjusted summary-based comparisons. The registry also reports adverse-event counts by group. Details of the sample-size justification, multiplicity strategy, missing-data methods, and full statistical plan are not reported.